CRSP

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Crispr Therapeutics AG

NASDAQ | CRSP

67.61

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 24, 2025)

$6.11B

Market Cap

-

P/E Ratio

-5.4

EPS

$78.48

52 Week High

$30.04

52 Week Low

HEALTHCARE

Sector

CRSP Chart

Recent Chart
Price Action

CRSP Technicals

Tags:

CRSP Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$75M
Total Revenue $35M
Cost Of Revenue $110M
Costof Goods And Services Sold $110M
Operating Income -$467M
Selling General And Administrative $73M
Research And Development $321M
Operating Expenses $504M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $19M
Income Before Tax -$363M
Income Tax Expense $3.6M
Interest And Debt Expense -
Net Income From Continuing Operations -$366M
Comprehensive Income Net Of Tax -
Ebit -$467M
Ebitda -$447M
Net Income -$366M

Revenue & Profitability

Earnings Performance

CRSP Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $2.2B
Total Current Assets $1.9B
Cash And Cash Equivalents At Carrying Value $298M
Cash And Short Term Investments $298M
Inventory -
Current Net Receivables $25M
Total Non Current Assets $305M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $0
Short Term Investments $1.6B
Other Current Assets $8.3M
Other Non Current Assets -
Total Liabilities $310M
Total Current Liabilities $88M
Current Accounts Payable $15M
Deferred Revenue -
Current Debt -
Short Term Debt $17M
Total Non Current Liabilities $222M
Capital Lease Obligations $224M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $224M
Other Current Liabilities $52M
Other Non Current Liabilities $3.4M
Total Shareholder Equity $1.9B
Treasury Stock -
Retained Earnings -$1.4B
Common Stock $2.7M
Common Stock Shares Outstanding $84M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$143M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $19M
Capital Expenditures $1.9M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$280M
Cashflow From Financing $332M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$366M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$75M
Total Revenue $35M
Cost Of Revenue $110M
Costof Goods And Services Sold $110M
Operating Income -$467M
Selling General And Administrative $73M
Research And Development $321M
Operating Expenses $504M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $19M
Income Before Tax -$363M
Income Tax Expense $3.6M
Interest And Debt Expense -
Net Income From Continuing Operations -$366M
Comprehensive Income Net Of Tax -
Ebit -$467M
Ebitda -$447M
Net Income -$366M

CRSP News

CRSP Profile

Crispr Therapeutics AG Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Crispr Therapeutics AG (CRSP) is a pioneering gene editing company leveraging its proprietary CRISPR/Cas9 technology to develop breakthrough therapies for serious genetic disorders, such as sickle cell disease and beta-thalassemia. Based in Zug, Switzerland, the company is actively expanding its clinical pipeline and forging strategic collaborations to translate its innovative science into effective treatments. With a robust portfolio and a commitment to improving patient outcomes, Crispr Therapeutics is positioned as a leader in the evolving biopharmaceutical industry, aiming to redefine the landscape of medicine through advanced gene editing solutions.

BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
WGRX
+185.43%
$1.14
TOVX
+1.63%
$0.34
YYAI
-14.98%
$0.07
VIVK
+11.91%
$0.29
F
+12.07%
$13.83
INTC
+0.31%
$38.28
YDKG
-15.04%
$0.06
BURU
+15.68%
$0.39
CGBS
-39.47%
$0.03
CENN
-0.74%
$0.21
DVLT
+43.15%
$3.22
VHAI
0.00%
$0.00
ASST
+27.28%
$1.10
NVDA
+2.25%
$186.26
NOK
+11.17%
$6.17
BITF
+10.68%
$4.61
TSLA
-3.39%
$433.72
AAL
+7.90%
$13.78
DNN
+3.29%
$2.82
RGTI
-1.90%
$38.84
ADTX
-28.06%
$0.21
T
+2.21%
$25.16
PLUG
+2.43%
$2.95
AMD
+7.63%
$252.92
RIG
+0.77%
$3.92
AXDX
-61.36%
$0.03
ABEV
-1.13%
$2.18
QBTS
+5.15%
$32.65
RF
+1.95%
$24.57
SMCI
-8.72%
$47.92
LAES
+22.55%
$7.01
CAN
+7.38%
$1.89
SOFI
+3.31%
$29.01
GRAB
+1.77%
$5.72
QLGN
+3.11%
$3.64
ONDS
+5.66%
$7.46
NUAI
+48.35%
$5.86
WTO
-7.14%
$0.06
TLRY
+0.67%
$1.49
QS
+14.73%
$16.82
SNAP
+1.01%
$7.95
ADAP
-7.57%
$0.06
CIFR
+19.73%
$20.66
JOBY
+1.29%
$15.67
AIRE
-22.42%
$0.76
ETHD
-3.40%
$3.83
ACHR
+3.52%
$11.29
IONZ
-4.02%
$3.82
RMBL
+60.50%
$3.21
AMZN
+1.41%
$224.21
RXRX
+5.41%
$6.04
NIO
+0.21%
$6.90
AAPL
+1.24%
$262.82
ADD
-25.47%
$0.05
VLY
+4.24%
$10.56
QUBT
-2.57%
$15.53
IREN
+12.60%
$62.90
GPUS
-0.28%
$0.38
RR
+12.17%
$6.08
AMC
-1.64%
$2.68
SRM
+53.27%
$10.30
PLTR
+2.29%
$184.63
NVTS
+3.37%
$14.07
BTBT
+4.97%
$3.90
UUUU
+0.47%
$21.36
BTG
-0.47%
$5.20
DFLI
+13.27%
$1.28
RVPH
+18.99%
$0.67
BBD
+0.14%
$3.35
HPE
+0.43%
$23.19
MARA
+1.66%
$19.54
CUTR
-10.19%
$0.09
PBR
-0.84%
$11.74
NAKA
+5.66%
$0.84
WU
+10.13%
$8.96
WLGS
-5.57%
$0.04
SOUN
-1.42%
$17.98
SCWO
+32.07%
$0.48
VZ
+1.14%
$38.84
PFE
+0.44%
$24.78
IONQ
+1.63%
$60.34
ETWO
0.00%
$3.30
RGTZ
+3.08%
$15.36
MU
+5.95%
$219.02
APLD
+9.01%
$33.38
RIVN
-0.67%
$13.00
WBD
-0.47%
$21.15
LUMN
+3.78%
$8.08
HOOD
+4.06%
$139.79
SMR
+0.37%
$37.70
IVZ
+1.43%
$23.00
AFMD
-34.94%
$0.18
BMNR
+2.25%
$50.30
ERIC
-0.31%
$9.44
KDLY
+10.41%
$0.79
MSAI
-28.77%
$0.96
BAC
+1.55%
$52.56
WULF
+5.67%
$13.61
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
WGRX
+185.43%
$1.14
TOVX
+1.63%
$0.34
YYAI
-14.98%
$0.07
VIVK
+11.91%
$0.29
F
+12.07%
$13.83
INTC
+0.31%
$38.28
YDKG
-15.04%
$0.06
BURU
+15.68%
$0.39
CGBS
-39.47%
$0.03
CENN
-0.74%
$0.21
DVLT
+43.15%
$3.22
VHAI
0.00%
$0.00
ASST
+27.28%
$1.10
NVDA
+2.25%
$186.26
NOK
+11.17%
$6.17
BITF
+10.68%
$4.61
TSLA
-3.39%
$433.72
AAL
+7.90%
$13.78
DNN
+3.29%
$2.82
RGTI
-1.90%
$38.84
ADTX
-28.06%
$0.21
T
+2.21%
$25.16
PLUG
+2.43%
$2.95
AMD
+7.63%
$252.92
RIG
+0.77%
$3.92
AXDX
-61.36%
$0.03
ABEV
-1.13%
$2.18
QBTS
+5.15%
$32.65
RF
+1.95%
$24.57
SMCI
-8.72%
$47.92
LAES
+22.55%
$7.01
CAN
+7.38%
$1.89
SOFI
+3.31%
$29.01
GRAB
+1.77%
$5.72
QLGN
+3.11%
$3.64
ONDS
+5.66%
$7.46
NUAI
+48.35%
$5.86
WTO
-7.14%
$0.06
TLRY
+0.67%
$1.49
QS
+14.73%
$16.82
SNAP
+1.01%
$7.95
ADAP
-7.57%
$0.06
CIFR
+19.73%
$20.66
JOBY
+1.29%
$15.67
AIRE
-22.42%
$0.76
ETHD
-3.40%
$3.83
ACHR
+3.52%
$11.29
IONZ
-4.02%
$3.82
RMBL
+60.50%
$3.21
AMZN
+1.41%
$224.21
RXRX
+5.41%
$6.04
NIO
+0.21%
$6.90
AAPL
+1.24%
$262.82
ADD
-25.47%
$0.05
VLY
+4.24%
$10.56
QUBT
-2.57%
$15.53
IREN
+12.60%
$62.90
GPUS
-0.28%
$0.38
RR
+12.17%
$6.08
AMC
-1.64%
$2.68
SRM
+53.27%
$10.30
PLTR
+2.29%
$184.63
NVTS
+3.37%
$14.07
BTBT
+4.97%
$3.90
UUUU
+0.47%
$21.36
BTG
-0.47%
$5.20
DFLI
+13.27%
$1.28
RVPH
+18.99%
$0.67
BBD
+0.14%
$3.35
HPE
+0.43%
$23.19
MARA
+1.66%
$19.54
CUTR
-10.19%
$0.09
PBR
-0.84%
$11.74
NAKA
+5.66%
$0.84
WU
+10.13%
$8.96
WLGS
-5.57%
$0.04
SOUN
-1.42%
$17.98
SCWO
+32.07%
$0.48
VZ
+1.14%
$38.84
PFE
+0.44%
$24.78
IONQ
+1.63%
$60.34
ETWO
0.00%
$3.30
RGTZ
+3.08%
$15.36
MU
+5.95%
$219.02
APLD
+9.01%
$33.38
RIVN
-0.67%
$13.00
WBD
-0.47%
$21.15
LUMN
+3.78%
$8.08
HOOD
+4.06%
$139.79
SMR
+0.37%
$37.70
IVZ
+1.43%
$23.00
AFMD
-34.94%
$0.18
BMNR
+2.25%
$50.30
ERIC
-0.31%
$9.44
KDLY
+10.41%
$0.79
MSAI
-28.77%
$0.96
BAC
+1.55%
$52.56
WULF
+5.67%
$13.61
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.